Strategy Tested | Study | Phase | Setting | Treatment | N. Patients |
---|---|---|---|---|---|
Immune-optimized anti-HER2 antibodies | SOPHIA NCT02492711 | III | HER2+ mBC progressed on HER2-targeted treatment | Randomized: -Chemotherapy+ Margetuximab -Chemotherapy+ Trastuzumab | 530 (active, not recruiting) |
Bispecific antibodies | NCT02829372 | I | Progressive HER2+ Solid Tumors | GBR1302 (CD3/HER2 bispecific mAb) | 60 (recruiting) |
Vaccines | NCT03387553 | I | During neoadjuvant treatment (HER2+ BC) | HER-2 Pulsed Dendritic cell vaccine | 24 (recruiting) |
NCT02061423 | I | Post-neoadjuvant residual disease HER-2+ BC | HER-2 Pulsed Dendritic cell vaccine | 7 (active, not recruiting) | |
NCT02063724 | I | Adjuvant (High Risk HER2+ BC) | HER-2 Pulsed Dendritic cell vaccine | 15 (active, not recruiting) | |
NCT00436254 | I | Stage III-IV HER2+ BC or OC | pNGVL3-hICD vaccine (plasmid-based DNA vaccine) + GM-CSF | 66 (active, not recruiting) | |
NCT01730118 | I | Solid tumors with 1–3+ HER2/Neu Expression | Adenoviral Transduced Autologous HER2/Neu Dendritic Cell Vaccine | 65 (recruiting) | |
NCT01376505 | I | Advanced solid tumors | Synthetic peptides of HER-2 comprising B cell epitopes with a Promiscuous T cell epitope of Measles Virus | 36 (recruiting) | |
NCT01355393 | I/II | Stage II-IV HER2+ BC | HER-2/neu peptide vaccine + rintatolimod and/or GM-CSF | 50 (active, not recruiting) | |
NCT00194714 | I/II | Stage IV HLA-A2+ HER2+ BC or OC receiving Trastuzumab | HER2 cytotoxic T-cell peptide-based vaccine | 20 (enrolling by invitation) | |
NCT01922921 | I/II | Stage IV HER2+ BC receiving HER2-targeted mAb | Randomized: -HER2 ICD peptide-based vaccine+polysaccharide-K -HER2 ICD peptide-based vaccine+Placebo | 31 (active, not recruiting) | |
NCT00343109 | II | HER2+ stage IIIB- IV BC receiving trastuzumab | HER-2/neu intracellular domain peptide-based vaccine mixed with GM-CSF | 38(active, not recruiting) | |
NCT00266110 | II | HLA-A0201+ HER2+ mBC | Dendritic cell Vaccine + GM-CSF + trastuzumab + vinorelbine | 17(active, not recruiting) | |
NCT03384914 | II | Adjuvant HER2+ BC | Randomized: -Dendritic Cell (DC1) Vaccine -pUMVC3-IGFBP2-HER2-IGF1R (WOKVAC) | 110 (recruiting) | |
NCT00640861 | NA | Treated Stage II/III MUC1+ HLA-A2+ BC | Randomized: combinations of MUC1/HER-2/Neu Peptide Based Immunotherapeutic Vaccines | 45 (active, not recruitng) | |
NCT02297698 | II | Adjuvant (High Risk HER2+ BC) | Randomized: Trastuzumab/GM-CSF +/− nelipepimut-S | 100 (recruiting) | |
Immune-stimulating agents concomitantly with trastuzumab | NCT03571633 | II | Operable HER2+ BC | Randomized: Paclitaxel/trastuzumab +/− Pegfilgrastim | 90 (not yet recruiting) |
NCT03112590 | I/II | HER2+ BC | IFN-γ + Paclitaxel+Pertuzumab+Trastuzumab | 48 (recruiting) | |
Cellular immunotherapy | NCT02843126 | I/II | Recurrent HER2 + BC | Randomized: Trastuzumab +/− NK immunotherapy | 30 (recruiting) |
NCT02713984 | I/II | Relapsed or refractory HER2+ solid tumors | anti-HER2 CAR-modified T cells | 60 (recruiting) |